Congrats to Mike V. Gormally, MD PhD on his very well deserved ASCO Young Investigator Award to support his research developing best in class #TCRs targeting recurrent #TP53 hotspot mutations! MSK Department of Medicine Memorial Sloan Kettering Cancer Center Conquer Cancer, the ASCO Foundation ASCO #Tcellpower

So proud! Immense gratitude to Chris and the rest of the Klebanoff_Lab for such fantastic mentorship, to Conquer Cancer, the ASCO Foundation for 💸💸💸 to support us, and all cancer patients HopeForStomachCancer and beyond, whose contributions are central to how we discover novel T cell therapies⬇️⬇️⬇️

Dr ⁦Mike V. Gormally, MD PhD⁩ with great work in SMARCA4 across cancers ⁦Memorial Sloan Kettering Cancer Center⁩ ⁦MSK Department of Medicine⁩ #ASCO24

Pioneering work from Dr. Christopher A. Klebanoff discussing innovations within TCR to enhance efficacy against cancer cells at the 2024 Nature Cancer Immunotherapy Conference at Harvard Medical School.

For readers interested in T-cell receptor therapies for targeting the intracellular cancer proteome, here's a recent review bit.ly/475y4R7 rdcu.be/dKCwy

In 1986, Dembic et al., again nature, report that transferring the TCR from one T cell to another “endowed the recipient cell with the specificity of the donor cell.” nature.com/articles/32023…

Many congratulations to our Dr. Sunil Acharya sunil acharya for his exciting research on CD70-targeting CAR NK cells, published in Cancer Discovery! Sunil and his co-authors showed that the incorporation of CD28 costimulation, which is normally absent in NK cells, in the CAR

Impressive results from the Rosenberg lab NCI Center for Cancer Research using TCR gene therapy targeting private neoantigens in patients with metastatic colorectal cancer. Tumor regression in majority of patients, including 3/7 (43%) objective responses. nature.com/articles/s4159…

A memorable night brining the Klebanoff_Lab together and celebrating Hannah’s contributions to the team over the past 3 years. Excited she’s remaining at Memorial Sloan Kettering Cancer Center GSK Graduate School for graduate school! #MSKFunFund #Tcellpower

Thank you Klebanoff_Lab Bhardwaj Lab Justin Eyquem Absolutely amazing discussions with an incredible group of scientists. Parker Institute for Cancer Immunotherapy

For readers interested in T cell receptor therapeutics for cancer, here's a comprehensive recent review bit.ly/475y4R7 rdcu.be/dPlAl

🚨An entire meeting dedicated to innovation and progress in solid tumor cell therapy!🚨 On behalf of my co-organizers and Society for Immunotherapy of Cancer, please save the date and spread the word! #ChristineBrown Jennifer Guerriero, PhD John Haanen Daniel Powell Lab @ UPENN Evan Weber #TIL #TCR #CAR #Synbio

🙌🧬It’s official: the first TCR gene therapy for the treatment of cancer received U.S. FDA approval this evening. A milestone event for the oncology community and the 2nd cell therapy approved for solid cancers! Adaptimmune #Tcellpower adaptimmune.com/investors-and-…

The FDA approved the first engineered T cell therapy, afami-cel, for the treatment of adults with synovial sarcoma. The clinical trial that resulted in the drug’s approval was led by Memorial Sloan Kettering Cancer Center sarcoma specialist and #CycleforSurvival funding recipient, Sandra D’Angelo, MD.

When you don't have new results to show in lab meeting so you improve your old presentation instead

All 9 episodes of “From Bench to Fireside” are now on Apple Podcasts! Get inspired by groundbreaking research, hear the stories behind the science and discover what's next in cancer treatment. Listen & subscribe: podcasts.apple.com/us/podcast/fro…

Recruiting a postdoc to study mechanisms of tolerance & immunity in the pregnant host. If you are passionate about this understudied area and excited to discover mechanisms of humoral tolerance to the placenta & fetus, do get in touch. (1/2)

Now accepting applications for our 2025 Cancer Biology & Cancer Engineering programs. Aspiring scientists & engineers will solve fundamental problems in biology & conduct research & develop technology that will help understand, diagnose, & treat cancer. bit.ly/3WUiuo1

Very excited to share recent updates from the Klebanoff_Lab on the immunogenicity and therapeutic targeting of recurrent 'public' neoantigens alongside some of the best and brightest in the neoantigen business! Memorial Sloan Kettering Cancer Center Parker Institute for Cancer Immunotherapy AACR #Tcellpower

Great advice on how to think like a scientist from Big Bird.